Is there resistance to dasatinib in the treatment of chronic myelogenous leukemia?

Dasatinib, as a tyrosine kinase inhibitor, is one of the important drugs for the treatment of chronic myelogenous leukemia (CML). However, like many other drugs, resistance to dasatinib can develop during treatment.

Dasatinib inhibits the activity of ABL kinase, thereby interfering with the molecular basis of abnormal proliferation and differentiation of CML cells to achieve the purpose of controlling disease progression. It is a second-generation tyrosine kinase inhibitor and is an important treatment option for patients who are resistant or intolerant to imatinib.

Although dasatinib may be very effective in initial treatment, some patients may develop resistance after long-term use. This is mainly due to the fact that tumor cells gradually adapt to the environment under the pressure of drugs and undergo genetic mutations or other biological changes, resulting in the weakening of the drug's killing effect on tumor cells.

When a patient develops drug resistance, it is first recommended to undergo genetic testing to understand the specific resistance mechanism. Based on the test results, the doctor can adjust the dosage or replace it with other effective drugs.

In some cases, doctors may consider using other drugs in combination to enhance the efficacy of dasatinib, or directly switching to other tyrosine kinase inhibitors, such as nilotinib. For patients who are taking dasatinib, doctors need to conduct regular hematological and molecular tests in order to detect signs of drug resistance in a timely manner and take appropriate treatment measures.

Dasatinib does have a risk of drug resistance in the treatment of chronic myelogenous leukemia. To combat this, patients need to work closely with their doctors and undergo regular check-ups and evaluations. Although dasatinib is an effective treatment for CML, drug resistance is a concern. Through scientific monitoring and treatment adjustment, this problem can be effectively dealt with and the patient's treatment effect and quality of life can be improved.